Articles tagged with Hiv Vaccines
Researchers characterize immune proteins that recognize and eliminate virus, providing insight into developing a potent Nab response against different HIV subtypes. Studies examine the efficacy of Nabs in blocking direct cell-to-cell transmission of HIV, highlighting the importance of controlling virus replication via this pathway.
A new study led by Beth Israel Deaconess Medical Center shows that a novel HIV-1 vaccine regimen provides complete protection against simian immunodeficiency virus in half of vaccinated non-human primates. The vaccine regimen involves a viral vector boosted with a purified envelope protein, demonstrating improved protection over previo...
A pre-clinical study of an HIV vaccine regimen showed complete protection from infection in half of the vaccinated non-human primates. The 'heterologous prime-boost' vaccine approach is being evaluated in a phase 1/2a clinical trial for safety and immunogenicity in healthy volunteers.
A new study found that certain immune responses may play a role in blocking systemic HIV infection after exposure. T-cell responses against specific HIV-1 antigens were significantly higher and more frequent among those who remained uninfected compared to those who became infected, associated with reduced risk of infection.
Researchers at Scripps Research Institute successfully test an experimental HIV vaccine candidate in mice, producing antibody precursors necessary to recognize and block HIV infection. The findings provide key information for the development of an effective AIDS vaccine.
Researchers suggest that a sequence of tailored immunizations could guide the immune response to develop special antibodies that can neutralize HIV. The approach targets the virus's binding site, which remains unchanged despite mutations.
Researchers at Sanford-Burnham Medical Research Institute have discovered a protein called polyglutamine-binding protein 1 (PQBP1) that recognizes HIV and initiates an immune response. The study suggests that designing a drug mimicking the PQBP1-HIV interface could create an effective vaccine environment, potentially preventing infection.
Researchers at Vanderbilt University have redesigned an antibody using a computer program, increasing its potency and ability to neutralize multiple strains of HIV. The study suggests that computer-redesigned antibodies may speed the search for an effective therapy or vaccine against HIV.
A vaccine targeting the viral protein Tat shows promise in boosting an HIV-infected patient's immune system, increasing CD4+ T cell count and reducing latent virus DNA load. The results suggest a new treatment scenario to investigate intensified antiretroviral therapy with a vaccine.
Researchers investigate how BAF protein defends against viral DNA attacks, discovering the virus's ability to turn off this key defensive mechanism. This understanding may lead to targeted therapies for viruses that inject DNA into cells.
Researchers have developed a new Ebola vaccine based on the 2014 virus strain, showing it to be safe and provoking an immune response. In a phase 1 clinical trial, participants receiving high doses of the vaccine had a 100% positive immune response rate.
The HVTN 100 trial aims to build on the RV144 results by testing a modified vaccine regimen with greater protection for southern Africa's predominant HIV subtype. The trial will enroll 252 HIV-uninfected adults and monitor safety and immune responses.
A new study found that fast-replicating HIV strains lead to more signs of acute inflammation and faster disease progression. The strain's replicative capacity affects immune system disruption and can inform vaccine development and eradication strategies.
A single-dose Ebola vaccine given to primates through their noses and lungs protected them against infection for at least 21 weeks. The vaccine's effectiveness could help prevent the spread of Ebola and other diseases through unintentional pricks.
The pneumococcal conjugate vaccine (PCV13) has significantly reduced serious infections, including those caused by antibiotic-resistant superbugs, among children under five years old. The vaccine's effectiveness led to the early achievement of the Healthy People 2020 goal of reducing antimicrobial-resistant invasive pneumococcal disease.
A recent clinical trial evaluated heterologous prime/boost regimens for preventative HIV vaccination, demonstrating strong anti-HIV immune responses in healthy volunteers. The results suggest that a regime combining NYVAC-B and rAd5-vectored vaccines yields better outcomes compared to other vaccine combinations.
A new preclinical trial will begin to confirm the HIV vaccine candidate's excellent results, led by Dr. Ruth Ruprecht and funded by the Bill & Melinda Gates Foundation. The study aims to provide mucosal protection and blood antibodies against infection.
Researchers have discovered a surprisingly diverse family of antibodies that can broadly neutralize different strains of HIV, providing new options for vaccine design. The findings offer clues on how to elicit high levels of these antibodies in people.
Researchers have identified a new vulnerability in the HIV armor that a vaccine could exploit, with an antibody called 35O22 preventing 62% of known strains from infecting cells. The discovery suggests it may be easier to elicit this antibody through vaccination compared to other broadly neutralizing antibodies.
Historic HIV vaccine trials have triggered an antibody response that lasts for two years, according to researchers at Duke University Medical Center. This response may provide protection against HIV infection.
Scientists have discovered novel properties of special HIV antibodies that can neutralize multiple strains of HIV. The study found that these 'broadly neutralizing antibodies' are more prevalent in HIV-infected individuals than previously thought, suggesting a possible vaccine strategy to elicit them.
A recent study in the Journal of Clinical Investigation found that an individual's genotype correlates with their ability to develop immunity to HIV in response to vaccination. Researchers identified single nucleotide variations in genes involved in antibody production, which were associated with protection against HIV infection.
Researchers at Duke University Medical Center found that two B-cell lineage antibodies teamed up to stimulate broadly neutralizing antibodies in people with HIV infection. This cooperative mechanism may lead to a global vaccine strategy by inducing high levels of such antibodies in approximately 20% of individuals with HIV infection.
A potential biomarker associated with participants who experienced a more profound viral load reduction after receiving the vaccine has been identified. The biomarker, anti-C5/gp41732-744 antibody levels above 4μg/ml, may be able to predict which patients will benefit most from the therapeutic HIV vaccine candidate Vacc-4x.
A team led by Scripps Research Institute scientists has received a $13 million grant to study antibodies to the human immunodeficiency virus (HIV) in pursuit of an effective vaccine. The goal is to elicit broadly neutralizing antibodies that can neutralize most circulating HIV strains.
A University of Nebraska-Lincoln team has developed a promising new approach for HIV vaccine development using an attenuated and genetically modified virus. The approach involves manipulating the virus' codons to rely on an unnatural amino acid, preventing the virus from replicating in the human body.
Researchers validated microbial translocation hypothesis in SIV-infected pigtail macaques, finding that sevelamer treatment reduced systemic LPS and activated peripheral CD4+ T cells. Sevelamer also lowered viral titers and coagulation biomarkers, suggesting a potential therapeutic strategy for HIV.
Scientists at the Scripps Research Institute have discovered that a single site on the surface protein of HIV can be targeted by an AIDS vaccine, potentially neutralizing nearly all strains of the virus. The study suggests that this approach could lead to a highly effective vaccine that targets a specific site on the Env protein.
Researchers at Simon Fraser University have found that HIV is slowly adapting to its human hosts in North America, a development with potential implications for vaccine design. The study, published in PLOS Genetics, suggests that the virus's adaptation rate may be too slow to pose a significant threat.
A clinical trial found that HIV-positive women build antibodies against HPV and experience no unusual safety issues after vaccination. The study's results counter doubts about the vaccine's effectiveness in this population, suggesting it is safe and beneficial for those with weakened immune systems.
Researchers are investigating HIV vaccines that failed to demonstrate efficacy and may have increased susceptibility to HIV infection. A new perspectives article highlights the need for risk-benefit analysis when developing new HIV vaccine candidates.
Two studies found that only one subclass of V1V2-directed IgG antibodies, the IgG3 subclass, is associated with antiviral responses linked to the reduced risk of HIV infection seen in the RV144 trial. More research is needed to determine whether these antibodies protected some vaccinees from HIV infection.
A scientific team discovered how the immune system makes a powerful antibody that blocks HIV infection of cells by targeting a site on the virus called V1V2. The new findings point toward a potentially more effective vaccine that would generate V1V2-directed HIV neutralizing antibodies.
Researchers at Scripps Research Institute developed a new method to design artificial proteins that can stimulate the production of virus-neutralizing antibodies. The approach was tested on a candidate vaccine against respiratory syncytial virus (RSV), showing promise in rhesus macaques.
A safe and effective HIV vaccine is necessary to control and potentially end the HIV/AIDS pandemic. Recent scientific advances offer promising areas for further exploration, including the discovery of broadly neutralizing antibodies and improved understanding of T-cell responses.
A safe and effective HIV vaccine is necessary to control and end the AIDS pandemic, according to a new commentary by NIAID Director Anthony S. Fauci. Recent advances in understanding broadly neutralizing antibodies and T-cell responses offer promising areas for further exploration.
Researchers found a mechanism that helps HIV evade antibodies and stabilize key proteins. By sulfating amino acids on the gp120 protein, the virus can be made more susceptible to neutralizing antibodies, which could lead to more effective HIV vaccines.
A recent animal vaccine study has provided valuable insights that may lead to the development of more effective HIV vaccines. The study found that antibodies targeting SIV spikes can prevent infection and identified clear measures of immune responses that predict protection.
Researchers at Emory Vaccine Center compared the molecular signatures induced by five different vaccines to predict vaccine effectiveness and stimulate immune responses. The study suggests that gene expression predictors are dependent on vaccine type, rather than universal.
Researchers at Weill Cornell Medicine and TSRI have determined the atomic-level structure of the tripartite HIV envelope protein, known as Env. The findings provide a detailed picture of the complex protein and its sites of vulnerability that could be targeted by future vaccines.
A new HIV vaccine has demonstrated partial protection against simian-human immunodeficiency virus in rhesus monkeys, with an 87-90% reduction in infection rate. The vaccine uses optimized antigens that mount antibody and cellular immune responses to diverse strains of the virus.
Researchers found that two HIV vaccine trials stimulated a critical immune response in infants, which has been linked to reduced HIV infection. The findings suggest that infant vaccination can elicit a robust anti-HIV envelope IgG immune response and highlight the importance of including pediatric populations in vaccine studies.
Researchers have developed a new tuberculosis vaccine that acts as a booster to the existing Bacille Calmette Guerin (BCG) vaccine, which is ineffective in many cases. The vaccine was tested in a phase one clinical study and showed a robust immune response in most trial participants.
Duke Medicine has been named a Vaccine and Treatment Evaluation Unit (VTEU) to evaluate vaccines, treatments, and diagnostics. The VTEU will focus on vaccine development for diseases other than HIV, with potential annual funding of up to $135 million.
Researchers at Scripps Research Institute discovered that an antibody binding to HIV likely targets the body's own proteins, complicating its development as a vaccine. The finding raises concerns about potential autoimmune diseases and self-reactivity in 4E10 antibodies.
A recent study by La Jolla Institute scientist Shane Crotty found that follicular helper T (Tfh) cells play a key role in generating broad neutralizing antibodies against HIV. The research showed a correlation between Tfh cell levels and antibody response, suggesting these cells may serve as an indicator for vaccine development.
Researchers at Oregon Health & Science University have developed an HIV/AIDS vaccine candidate that appears to completely clear the AIDS-causing virus from the body. The vaccine uses a modified form of cytomegalovirus to generate T-cells capable of targeting and eliminating infected cells.
Three NIH scientists, Drs. Warner Greene, Richard Sutton, and Timothy Cardozo, receive $500,000 each to support groundbreaking HIV/AIDS research. Their projects focus on modifying the immune response to prevent further CD4 T-cell loss, identifying protective genes against HIV infection, and developing a combined cocaine/HIV vaccine.
Researchers analyzed data from the RV144 HIV vaccine trial, which showed a 31% protection rate. They found that specific antibodies may interfere with the protective effects of other antibodies, reducing the vaccine's efficacy. This discovery can inform future vaccine development strategies to overcome these limitations.
Tracking an early immune response, researchers chart a new route for developing a long-sought HIV vaccine that boosts the body's ability to neutralize the virus. The study reveals the co-evolution of antibodies and virus in a person whose immune system mounted a broad attack against the pathogen.
Researchers have identified a key player in the development of broadly neutralizing antibodies against HIV, paving the way for potential vaccine discovery. By studying the co-evolution of HIV and an individual's immune response, scientists can identify target proteins to include in vaccines.
Researchers from Ragon Institute develop a computational method to analyze viral protein sequences, identifying vulnerabilities that could be exploited for vaccine development. The approach uses spin glass models and fitness landscapes to predict the prevalence of mutant proteins, providing a new way to design effective HIV vaccines.
Researchers at King's College London have developed an injection-free vaccine technique that uses dried live vaccines delivered to the skin without needles, offering a potential solution to global vaccine challenges. The technique has been shown to be effective in inducing immune responses comparable to traditional needle-based methods.
The ACIP has updated its recommended 2013 adult immunization schedule to include new guidelines for the use of pneumococcal conjugate and influenza vaccines. The updated schedule also recommends routine Tdap vaccination for adults aged 65 or older, pregnant women, and all patients over 6 months old against influenza.
A study has provided new clues for designing a more effective HIV vaccine by analyzing the structure of antibody-virus complexes produced in vaccine recipients. The researchers found that antibodies targeting specific regions of the virus are associated with decreased transmission of HIV.
Researchers have gained additional insights into an HIV vaccine that help explain its successes and failures, providing new options for vaccine designers to strengthen the drug. The study found that the vaccine-induced antibodies recognized virus-infected cells and flagged them for an attack by other immune cells.
A genetically-engineered vaccine aims to prevent HIV infection by continually producing disease-fighting cells. The new approach could provide long-term protection and potentially be adapted for use against other infections.
A new study found that the RV144 vaccine was effective in preventing certain HIV viruses, particularly those carrying specific genetic footprints. The vaccine's immune response targeted the Env-V2 region, leading to increased efficacy of up to 80 percent.
Researchers at OHSU's Vaccine and Gene Therapy Institute studied the mechanism behind protection offered by slightly weakened monkey AIDS virus versions that were too risky for human use. The study reveals that anti-viral T cells in lymphoid tissue are responsible for this protection, which is lost when the virus is further weakened.
Lawrence Corey, a renowned expert in virology and immunology, has been honored with the Cubist-ICAAC Award for his pioneering work on herpes viruses, HIV, and cancer. His research has led to significant advances in antiviral therapy and vaccine development.